These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 30569441

  • 1. Clinical value of 18F-FDG-PET/CT in suspected serious disease with special emphasis on occult cancer.
    Caspersen KB, Giannoutsou N, Gerke O, Alavi A, Høilund-Carlsen PF, Hess S.
    Ann Nucl Med; 2019 Mar; 33(3):184-192. PubMed ID: 30569441
    [Abstract] [Full Text] [Related]

  • 2. Diagnostic value of diffusion-weighted imaging and 18F-FDG-PET/CT for the detection of unknown primary head and neck cancer in patients presenting with cervical metastasis.
    Noij DP, Martens RM, Zwezerijnen B, Koopman T, de Bree R, Hoekstra OS, de Graaf P, Castelijns JA.
    Eur J Radiol; 2018 Oct; 107():20-25. PubMed ID: 30292267
    [Abstract] [Full Text] [Related]

  • 3. Role of 18 F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in malignant ovarian germ cell tumors: a single-center experience with long term follow-up.
    Dolci C, Ceppi L, Guerra L, Crivellaro C, Lamanna M, Adorni M, Elisei F, Bonazzi CM, Sina F, Fruscio R, Messa C.
    Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
    [Abstract] [Full Text] [Related]

  • 4. Prediction of survival and evaluation of diagnostic accuracy whole body 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the detection carcinoma of unknown primary origin.
    Tamam MO, Mulazimoglu M, Guveli TK, Tamam C, Eker O, Ozpacaci T.
    Eur Rev Med Pharmacol Sci; 2012 Dec; 16(15):2120-30. PubMed ID: 23280029
    [Abstract] [Full Text] [Related]

  • 5. 18F-FDG PET/CT to differentiate malignant necrotic lymph node from benign cystic lesions in the neck.
    Abadi P, Johansen A, Godballe C, Gerke O, Høilund-Carlsen PF, Thomassen A.
    Ann Nucl Med; 2017 Feb; 31(2):101-108. PubMed ID: 27921286
    [Abstract] [Full Text] [Related]

  • 6. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial.
    Robin P, Le Roux PY, Planquette B, Accassat S, Roy PM, Couturaud F, Ghazzar N, Prevot-Bitot N, Couturier O, Delluc A, Sanchez O, Tardy B, Le Gal G, Salaun PY, MVTEP study group.
    Lancet Oncol; 2016 Feb; 17(2):193-199. PubMed ID: 26672686
    [Abstract] [Full Text] [Related]

  • 7. Clinical value of whole-body F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with carcinoma of unknown primary.
    Wang G, Wu Y, Zhang W, Li J, Wu P, Xie C.
    J Med Imaging Radiat Oncol; 2013 Feb; 57(1):65-71. PubMed ID: 23374557
    [Abstract] [Full Text] [Related]

  • 8. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
    Han A, Xue J, Hu M, Zheng J, Wang X.
    Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
    [Abstract] [Full Text] [Related]

  • 9. Whole-body 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) for staging locally advanced breast cancer: A prospective study from a tertiary cancer centre in south India.
    Gajjala SR, Hulikal N, Kadiyala S, Kottu R, Kalawat T.
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [Abstract] [Full Text] [Related]

  • 10. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients.
    Lee DY, Lee CH, Seo MJ, Lee SH, Ryu JS, Lee JJ.
    Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850
    [Abstract] [Full Text] [Related]

  • 11. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K.
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [Abstract] [Full Text] [Related]

  • 12. Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma.
    Alongi P, Evangelista L, Caobelli F, Spallino M, Gianolli L, Midiri M, Picchio M.
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):85-94. PubMed ID: 28828589
    [Abstract] [Full Text] [Related]

  • 13. DaPeCa-3: promising results of sentinel node biopsy combined with (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in clinically lymph node-negative patients with penile cancer - a national study from Denmark.
    Jakobsen JK, Alslev L, Ipsen P, Costa JC, Krarup KP, Sommer P, Nerstrøm H, Toft BG, Høyer S, Bouchelouche K, Jensen JB.
    BJU Int; 2016 Jul; 118(1):102-11. PubMed ID: 26216234
    [Abstract] [Full Text] [Related]

  • 14. Comparison of 18F-FDG PET/CT scan and 99mTc-MDP bone scintigraphy in detecting bone metastasis in head and neck tumors.
    Al-Bulushi NK, Abouzied ME.
    Nucl Med Commun; 2016 Jun; 37(6):583-8. PubMed ID: 26813992
    [Abstract] [Full Text] [Related]

  • 15. Whole-Body 18F-FDG PET/CT Is Superior to CT as First-Line Diagnostic Imaging in Patients Referred with Serious Nonspecific Symptoms or Signs of Cancer: A Randomized Prospective Study of 200 Patients.
    Lebech AM, Gaardsting A, Loft A, Graff J, Markova E, Bertelsen AK, Madsen JL, Andersen KF, Benzon EV, Helms M, Mathiesen LR, David KP, Kronborg G, Kjaer A.
    J Nucl Med; 2017 Jul; 58(7):1058-1064. PubMed ID: 28082437
    [Abstract] [Full Text] [Related]

  • 16. 18F-FDG PET/CT in Autosomal Dominant Polycystic Kidney Disease Patients with Suspected Cyst Infection.
    Pijl JP, Glaudemans AWJM, Slart RHJA, Kwee TC.
    J Nucl Med; 2018 Nov; 59(11):1734-1741. PubMed ID: 29653972
    [Abstract] [Full Text] [Related]

  • 17. Role of 18F-FDG PET/CT in the detection of primary malignancy in patients with bone metastasis of unknown origin.
    Budak E, Yanarateş A.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020 Nov; 39(1):14-19. PubMed ID: 31744788
    [Abstract] [Full Text] [Related]

  • 18. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G.
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [Abstract] [Full Text] [Related]

  • 19. Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients.
    Kristensen SB, Hess S, Petersen H, Høilund-Carlsen PF.
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2056-63. PubMed ID: 26194717
    [Abstract] [Full Text] [Related]

  • 20. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging 18F-FDG PET/CT.
    Okuyucu K, Ince S, Alagoz E, Emer O, San H, Balkan E, Ayan A, Meric C, Haymana C, Acıkel C, Gunalp B, Karacalioglu AO, Arslan N.
    Hell J Nucl Med; 2016 Dec; 19(3):208-217. PubMed ID: 27824959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.